NitroMed BiDil
Executive Summary
NitroMed acquires BiDil (isosorbide dinitrate/hydralazine) NDA and related intellectual property from Jay Cohn, MD, University of Minnesota, who will retain royalty rights. Medco filed the BiDil NDA for reduction of mortality and treatment of congestive heart failure in July 1996, but returned the rights to Cohn in 1998. NitroMed plans to amend the existing NDA to seek an indication for treatment of CHF in African-American patients, based on new data showing that the mortality of black patients receiving hydrazaline plus isosorbide dinitrate was reduced, the company said